DYRK1A and Cognitive impairment: Additionally, leucettinib‐21, a DYRK1A inhibitor.,60, 61 is in phase 1 trials to address cognitive deficits associated with DSAD by targeting overactive DYRK1A kinase, with plans to progress to phase 2A.59, 62